Poster Session II - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.04 - THROMBOLYSIS P627 - ESOC25-1710 COST-EFFECTIVENESS OF THROMBECTOMY WITH OR WITHOUT ALTEPLASE FOR LARGE VESSEL OCCLUSION STROKE ACROSS 16 COUNTRIES: A META-ANALYSIS CONSIDERING TIME-TO-TREATMENT Chi Nguyen 1,2 , Fabiano Cavalcante 3 , Kilian Treurniet 3,4 , Manon Kappelhof 4 , Wenjie Zi 5 , Pengfei Yang 6,7 , Kentaro Suzuki 8 , Urs Fischer, Conor Houlihan 9 , Peter Mitchell 9 , Bernard Yan 9 , Erik Buskens 1,2 , Maarten Uyttenboogaart 1 , Charles Majoie 4 , Maarten Lahr 1,10 1 University Medical Center Groningen, Groningen, Netherlands, 2 Faculty of Economics and Business, University of Groningen, Groningen, Netherlands, 3 Haaglanden Medical Center, Hague, Netherlands, 4 Amsterdam University Medical Center, location University of Amsterdam, Amsterdam, Netherlands, 5 Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China, 6 Changhai Hospital, Naval Medical University, Changhai, China, 7 Oriental Pan-Vascular Devices Innovations College, University of Shanghai for Science and Technology, Shanghai, China, 8 Nippon Medical School, Tokyo, Japan, 9 The Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia, 10 Aletta Jacobs School of Public Health, University of Groningen, Groningen, Netherlands Background and Aims: In stroke patients presenting to thrombectomy-capable stroke centers, the benefit of combining intravenous thrombolysis (IVT) with alteplase and thrombectomy is time-dependent
Gastrointestinal upset and transient anxiety have also been documented in clinical observation
Emerging Non-Invasive Therapies The biggest game-changer in 2025 has been the rise of non-invasive and regenerative therapies, with Platelet-Rich Plasma (PRP) therapy outshining all
The peptides frequently being referenced in reclassification conversations include: AOD-9604 BPC-157 Emideltide (DSIP Delta Sleep-Inducing Peptide) Epitalon (Epithalamin) GHK-Cu (Copper Peptide) Kisspeptin-10 KPV MOTS-C Semax Selank TB-500 (Thymosin Beta-4 Fragment) Thymosin Alpha-1 Despite public discussion, these peptides remain categorized as Category 2 under current FDA policy and are not eligible for patient-specific 503A compounding
But I also back this up with other tests that look at how your body utilises B12 to check you have enough
